Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe

Schlagenhauf, Patricia; Hatz, Christoph; Behrens, Ron; Visser, Leo; Funk, Maia; Holzer, Benedikt; Beck, Bernhard; Bourquin, Cathérine; Etter, Hermann; Furrer, Hansjakob; Genton, Blaise; Landry, Pierre; Chappuis, Francois; Loutan, Louis; Stössel, Ulrich; Jeschko, Eva; Rossanese, Andrea; Nothdurft, Hans Dieter (2015). Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe. Travel medicine and infectious disease, 13(2), pp. 192-196. Elsevier 10.1016/j.tmaid.2015.03.010

[img] Text
1-s2.0-S1477893915000459-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Since its introduction to the market in 1985, mefloquine has been used for malaria chemoprophylaxis by more than 35 million travellers. In Europe, in 2014, the European Medicines Agency (EMA) issued recommendations on strengthened warnings, prescribing checklists and updates to the product information of mefloquine. Some malaria prevention advisors question the scientific basis for the restrictions and suggest that this cost-effective, anti-malarial drug will be displaced as a first-line anti-malaria medication with the result that vulnerable groups such as VFR and long-term travellers, pregnant travellers and young children are left without a suitable alternative chemoprophylaxis. This commentary looks at the current position of mefloquine prescribing and the rationale of the new EMA recommendations and restrictions. It also describes the new recommendations for malaria prophylaxis that have been adapted by Switzerland, Germany, Austria and Italy where chemoprophylaxis use is restricted to high-risk malaria-endemic areas.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Furrer, Hansjakob

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1477-8939

Publisher:

Elsevier

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

27 May 2015 14:43

Last Modified:

19 Oct 2015 11:08

Publisher DOI:

10.1016/j.tmaid.2015.03.010

PubMed ID:

25825015

Uncontrolled Keywords:

Mefloquine; European Medicines Agency; Adverse events; Malaria prophylaxis

BORIS DOI:

10.7892/boris.67644

URI:

https://boris.unibe.ch/id/eprint/67644

Actions (login required)

Edit item Edit item
Provide Feedback